🕒 Last update: loading…16/11/2026

Stock Bayer Aktiengesellschaft BAYN.DE

Bayer Aktiengesellschaft — Investlytic score 1/5 on the five criteria.

-
-
20/ 100
Score Investlytic · 5 criteria

Analysis in progress…

Investlytic score: 1/5 criteria met. Data as of 01/11/2026.

  • ❌ Price trend failed
  • ⚠️ Mixed growth
  • ❌ Debt failed
  • ✅ P/E passed
  • ❌ Correction failed

Price trend

Overall trend (8 years): insufficient progression (less than x1.5).

Price change 2018 → 2019: 20.23%

Price change 2019 → 2020: -33.87%

Price change 2020 → 2021: -2.39%

Price change 2021 → 2022: 2.83%

Price change 2022 → 2023: -30.42%

Price change 2023 → 2024: -42.58%

Price change 2024 → 2025: 91.66%

Price change 2025 → 2026: 34.53%

Price change 2026 (year to date): 31.20%

Financial growth

Revenue CAGR (8 years): 3.13%

Earnings CAGR (8 years): N/A

Growth status: positive trend (>1%/yr) in revenue, earnings data insufficient/N/A.

Debt

Debt-to-equity ratio: 1.44

Debt/equity > 0.5 (maximum threshold).

P/E (Price/Earnings)

P/E ratio: 10.30

P/E < 25.0 (maximum threshold).

Correction (6 months)

Current correction: 6.69% from the high over 6 months.

Insufficient correction (< 10.0%).

WATCH
The stock is currently being evaluated.

Criteria of the Investlytic model

- / 5
🔒

Investlytic rating reserved for members

Score out of 100, model verdict (buy, watch, sell) and details of the 5 criteria · visible with a free account.

02

Price trend

Price & trend

Interactive chart →
Loading chart…

⚖️ Comparison with the market

All stocks →
StockP/EDette/FPRevenue growthRating
Bayer AG11.51.44+1.8 %🔒
Boston Scientific Corporation13.80.51+6.5 %–
Cencora, Inc.19.47.13+9.6 %–
Becton, Dickinson and Company16.30.76+6.5 %–
Lonza Group AG41.60.50+6.1 %–

Data from the Investlytic screener. The rating of the stock being viewed is reserved for members.

03

Detailed analysis · Price trend

-

🔒

Reserved for members

Global model trend and annual price variations · visible with a free account.

04

Revenues & profits

Revenue and net income

🔒

Reserved for members

Chart of revenues and net income over 8 periods · real data, no estimates.

05

Financial indicators

🔒

Reserved for members

18 financial indicators analyzed by groups of criteria: valuation, profitability, growth, solidity, dividend, and momentum.

06

Annual financial statements

Fiscal yearRevenueNet income Net marginEPSRevenue growth
🔒

Reserved for members

Complete annual financial statements: revenue, net income, margin, and EPS over 8 fiscal years.

+

Key reported figures

Revenue, net income and net margin reported by Bayer Aktiengesellschaft over the latest fiscal years.

Revenue
50.2 bn USD
fiscal year 2025
Net income
-4.0 bn USD
fiscal year 2025
Net margin
-7.9 %
fiscal year 2025
Average annual growth
+1.9 %
Revenue growth over 5 years
Average annual growth
-0.1 %
Revenue growth over 10 years
Market cap
61.2 bn USD
Fiscal yearRevenueNet incomeNet marginRevenue growth
202045.6 bn-11.6 bn-25.4 %n/a
202148.6 bn1.1 bn2.3 %+6.5 %
202255.9 bn4.6 bn8.2 %+15.1 %
202352.5 bn-3.2 bn-6.2 %-6.1 %
202451.4 bn-2.8 bn-5.5 %-2.2 %
202550.2 bn-4.0 bn-7.9 %-2.2 %

Amounts converted to USD. Source: published annual accounts, collected on 13/11/2026.

+

Accounts and financial health

Balance sheet and cash flow published by Bayer Aktiengesellschaft over the last fiscal years, strength scores and valuation by discounted cash flow (DCF).

Overview
fragile accounts
according to Altman Z, Piotroski and net debt
Altman Z-score
0.97
risk zone (below 1.81)
Piotroski Score
3 / 9
0 to 3: fragile accounts
DCF Value
12.09 EUR
DCF below share price · share price 56.56 EUR, gap -78.6 %
Net Debt / EBITDA
5.70 x
high debt
Fiscal year20212022202320242025
Cash and investments7.7 bn10.2 bn10.6 bn8.1 bn7.9 bn
Total Debt39.5 bn41.6 bn44.8 bn40.7 bn37.4 bn
Net Debt35.0 bn36.5 bn38.9 bn34.6 bn30.8 bn
Equity33.0 bn38.8 bn32.9 bn31.9 bn25.9 bn
Total assets120 bn125 bn116 bn111 bn111 bn
Operating cash flow5.1 bn7.1 bn5.1 bn7.4 bn4.6 bn
Investments (capex)2.6 bn2.9 bn2.8 bn2.8 bn2.5 bn
Free cash-flow2.5 bn4.1 bn2.4 bn4.6 bn2.1 bn
Share buybacks0024.0 m16.0 m14.0 m
Dividends paid2.0 bn2.0 bn2.4 bn131 m127 m

Amounts in EUR, currency of the published accounts.

Trailing 12-month ratios

Price / earnings (P/E)-38.48 x
Price / book value1.90 x
Return on Equity (ROE)-5.1 %
Return on Invested Capital (ROIC)6.2 %
Net margin-3.2 %
Debt / equity1.49 x
Current ratio1.35 x
Interest coverage2.17 x
Free cash-flow yield0.9 %

Altman Z: default risk estimated from the balance sheet and earnings. Piotroski: 9 tests on profitability, debt and efficiency. DCF: estimated value from discounted future cash flows, a model and not a forecast. Source: annual accounts published by the company, data as of 16/11/2026.

+

Valuation and competitors

Bayer Aktiengesellschaft compared with its sector on the same exchange and with its main competitors.

Company P/E
11.7
64.0 % below the sector
Sector median P/E
32.5
healthcare, Xetra
Sector over 10 years
26.9
10-year median, range 20.7 to 68.4

Direct competitors

CompanyMarket cap (USD)P/ENet margin
Bayer Aktiengesellschaft60.9 bn11.5-7.9 %
Merck KGaA MRK.DE72.1 bn17.712.4 %
BASF Se BAS.DE52.2 bn28.22.7 %
Dermapharm Holding SE DMP.DE2.1 bn14.011.4 %
DSM-Firmenich AG DSFIR.AS29.9 bnn/a-12.0 %
Novartis AG NOVN.SW306 bn19.425.6 %
Sector median (Xetra)32.5

Trailing 12-month P/E. Sector: median of companies in the same sector listed on the same exchange, collected on 16/11/2026. Competitors: comparable companies named by the data provider.

+

Analyst consensus and forecasts

What the financial analysts covering Bayer Aktiengesellschaft publish: ratings, price targets and earnings forecasts.

Majority rating
hold
3 analysts

Breakdown of ratings

strong buy 0buy 1hold 2sell 0strong sell 0

Price targets: published for companies listed in the United States only.

Analyst forecasts

Fiscal yearRevenueNet incomeExpected EPS (range)P/E on this EPSAnalysts
202645.8 bn4.5 bn4.51 (4.36 / 4.71)12.312
202747.1 bn4.8 bn4.79 (4.55 / 5.42)11.612
202848.6 bn5.3 bn5.36 (4.21 / 6.97)10.49

Amounts in EUR, the reporting currency.

Track record against expectations: reported EPS above consensus 10 times over the last 12 releases.

Source: ratings and forecasts published by analysts, collected on 14/11/2026. An analyst rating or target is not a guarantee.

+

Dividends and earnings

Bayer Aktiengesellschaft: dividend history, last distributions, stock splits and earnings releases.

Frequency
annual
Last dividend
0.110 EUR
ex-dividend on 27/04/2026
Last 12 months
0.110 EUR
number of payments: 1
Yield
0.3 %
on the last known price
Years of increases
0
consecutive
Years of payments
26
uninterrupted
00.701.402.102.802007 : 0.984 EUR2008 : 1.33 EUR20082009 : 1.38 EUR2010 : 1.38 EUR20102011 : 1.48 EUR2012 : 1.62 EUR20122013 : 1.87 EUR2014 : 2.07 EUR20142015 : 2.21 EUR2016 : 2.46 EUR20162017 : 2.66 EUR2018 : 2.76 EUR20182019 : 2.80 EUR2020 : 2.80 EUR20202021 : 2.00 EUR2022 : 2.00 EUR20222023 : 2.40 EUR2024 : 0.110 EUR20242025 : 0.110 EUR2026 : 0.110 EUR2026

Annual dividend per share (EUR), adjusted for splits. Light bar: current year, incomplete. Red bar: lower than the previous year.

Latest ex-dividend dates

Ex-dividendAmountPayment
27/04/20260.110 EUR29/04/2026
28/04/20250.110 EUR30/04/2025
29/04/20240.110 EUR02/05/2024
02/05/20232.40 EUR04/05/2023
02/05/20222.00 EUR04/05/2022
28/04/20212.00 EUR30/04/2021
29/04/20202.80 EUR04/05/2020
29/04/20192.80 EUR02/05/2019

Earnings releases

DatePublished EPSExpected EPSSurprise
03/11/20260.310.39-19.9 %
04/08/20260.940.76+23.0 %
12/05/20262.692.30+17.0 %
04/03/20260.630.39+60.7 %
10/11/20250.580.37+55.7 %
06/08/20251.240.91+36.6 %

Stock splits

DateOperation
06/06/2018split: 127 shares for 125
03/06/1996split: 10 shares for 1

Factual data: ex-dividend history and earnings calendar, as of 15/11/2026. A past dividend does not guarantee the next one.

+

Who owns the stock

Free float, institutional investors, large funds, executives and elected officials: declared positions in Bayer Aktiengesellschaft.

Free float
100.0 %
share of freely traded shares

Sources: 13F filings (quarter shown), executives' Form 4 filings and US Congress members' disclosures, collected on 07/11/2026. Detailed disclosure obligations mainly apply to companies listed in the United States.

+

PEA and practical information

PEA eligibility
likely
head office in the EU or EEA, listed on a European exchange
Listing exchange
Xetra
IPO: 16/12/1996
ISIN code
DE000BAY0017
Workforce
90,587
full-time employees
Chief executive
William N. Anderson
Next earnings
24/02/2027

Rule applied: the French PEA accepts shares of companies headquartered in the European Union or the European Economic Area and subject to corporate income tax; ADRs and tax-exempt property companies (SIIC) are excluded. The institution holding the PEA confirms eligibility.

?

Frequently asked questions about Bayer Aktiengesellschaft

What is the Bayer Aktiengesellschaft share price?

Latest recorded price: 56.52 EUR on 13/11/2026, for a market cap of 61.2 bn USD.

What is the revenue of Bayer Aktiengesellschaft?

50.2 bn USD for fiscal year 2025, with net income of -4.0 bn USD (net margin -7.9 %).

Does Bayer Aktiengesellschaft pay a dividend?

Yes. Latest dividend: 0.110 EUR per share, ex-dividend on 27/04/2026. Over 12 months: 0.110 EUR. Yield on the latest known price: 0.3 %.

When does Bayer Aktiengesellschaft report its next earnings?

The next release is expected on 24/02/2027. EPS expected by analysts: 0.60.

What do analysts say about Bayer Aktiengesellschaft?

Out of 3 analysts: 1 buy or strong buy, 2 hold, 0 sell or strong sell.

What is the P/E ratio of Bayer Aktiengesellschaft?

Trailing 12-month P/E of 11.7, against 32.5 for the sector median on the same exchange (10-year median: 26.9).

Is Bayer Aktiengesellschaft stock eligible for the French PEA?

Likely: the company is headquartered in the European Union or the European Economic Area (ISIN DE000BAY0017) and the stock is listed on a European exchange. The institution holding the PEA confirms eligibility.

How many employees does Bayer Aktiengesellschaft have?

90,587 full-time employees according to the latest published profile.

Who runs Bayer Aktiengesellschaft?

William N. Anderson is the company's chief executive.

07

Similar stocks